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The glucagon-like peptide-1 receptor (GLP-1 receptor) mediates important eﬀects on peripheral tissues and the central nervous
system. It seems one of the most promising therapeutic targets for treatment of diabetes mellitus type 2. Surprisingly, very little
is known about the cellular mechanisms that regulate its function in vivo. One of the approaches to study receptor dynamics,
expression, or signaling is using GFP-tagged ﬂuorescent proteins. In this study, we synthesized and characterized N-terminally
GFP-tagged GLP-1 (GFP-GLP-1) receptor in CHO cells. We demonstrated that GFP-GLP-1 receptor is weakly expressed in the
plasma membranes and is functionally coupled to adenylyl cyclase via heterotrimeric G-proteins, similarly as its wild type.
Copyright © 2009 A. Bavec and A. Liˇ car. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The glucagon-like peptide-1 (GLP-1) receptor mediates the
eﬀects of GLP-1(7-36)amide or GLP-1(7-37) on peripheral
tissues, such as the stimulation of glucose-induced insulin
secretion by pancreatic β-cells [1], arterial blood pressure,
heart rate [2], and lung surfactant synthesis [3], and in the
central nervous system it exerts eﬀects on food and water
intake [4] and enhances associative and spatial learning [5].
GLP-1 also induces β-cells proliferation and is protective
against apoptosis in both β-cells and neurons [6]. GLP-
1 has therapeutic potential; it stimulates insulin secretion
and lowers plasma glucose in patients with noninsulin-
dependentdiabetesmellitustype2[7,8].Moreover,exendin-
4, an exogenous GLP-1 receptor agonist isolated from the
Gila monster lizard, has very similar eﬀects [9, 10] and has
recently been approved for the treatment of type 2 diabetes.
GLP-1 receptor is a member of the G-protein coupled
receptors (GPCRs) and is classiﬁed within secretin/vaso-
intestinal peptide (VIP) receptor family B [11, 12]. GLP-
1 receptor-mediated signaling involves activation of at least
two signaling pathways: (i) adenylyl cyclase/cAMP/protein
kinase A pathway which increases the level of cAMP [13–
15], inhibits the KATP channels in β-cells [16, 17], enhances
currents through voltage-dependent Ca2+ channels [16, 18],
and increases the level of free cytosolic calcium in cAMP
dependent manner [19] is primarily involved in glucose-
stimulated insulin secretion, and (ii) phosphatydilinositol 3-
kinase/extracellular signal-related kinase/protein kinase Cξ
pathway, which aﬀects β-cell insulin gene transcription and
proliferation [20, 21]. In addition, some potential cross talk
between these two pathways has been linked to phosphodi-
esterase [22] and cAMP-GEFII-Rim2 complex [23]. GLP-1
might also stimulate release of inositol trisphosphate (IP3)-
sensitive Ca2+ stores because it increases inositol phosphate
production in COS-7 cells transfected with the recombinant
GLP-1 receptor [14]. Overexpressed GLP-1 receptor couples
to diﬀerent types of α subunits of G-proteins in Chinese
hamster ovary cells [24] and sf9 cells [25]. Point and
block deletion mutations of the receptor and peptide-based
interaction mapping of the receptor revealed the importance
of the third intracellular (IC3)l o o pi na c t i v a t i o no fG -
proteins and adenylyl cyclase [25–29].
Surprisingly, very little is known about the regulation of
membrane expression and traﬃcking of the GLP-1 receptor
invivo.Accordingtoourknowledgeonlyonepaperdiscusses
that GFP-tagged GLP-1 receptor interacts with caveolin-
1 in association that is necessary for receptor traﬃcking2 Journal of Biomedicine and Biotechnology
to the cell membrane in HEK 293 and MIN6 cells [30].
Works on cellular localization are done with C-terminally
GFP-tagged GLP-1 (GLP-1-GFP) receptor [30, 31]. This
GLP-1 receptor-GFP neither is displaying the same kinetic
data as its wild type nor is fully characterized regarding
receptor binding data, G-protein activation and coupling
to its downstream eﬀectors such as adenylyl cyclase or
phospholipase C. However, the physiological relevance of
these studies obtained with C-terminally GFP-tagged GLP-1
receptorisquestionable;therefore,furtherstudiesareneeded
to clarify expression and traﬃcking of the GLP-1 receptor in
vivo.
In this study, we used CHO cells to characterize N-
terminally GFP-tagged GLP-1 (GFP-GLP-1) receptor. We
demonstratedthatGFP-GLP-1receptorislocalizedinplasma
membranes and is functionally coupled to adenylyl cyclase
via heterotrimeric G-proteins, similarly as its wild type.
2.MaterialsandMethods
2.1. Cell Cultures. CHO cells were grown as monolayer
culture in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (Sigma F2442),
8,9mg/L L-alanine, 15,0mg/L L-asparagine, 13,3mg/L L-
aspartatic acid, 14,7mg/L L-glutamatic acid, 7,5mg/L
glicine, 11,5mg/L L-proline, 10,5mg/L L-serine, and 2mM
L-glutamine at 37◦Ci na5 %C O 2 atmosphere.
Rinm5FcellsweregrownasmonolayercultureinRPMI-
1640 medium supplemented with 10% fetal bovine serum,
2mM L-glutamine, 100 units/mL penicillin, and 100μg/mL
streptomycin at 37◦Ci na5 %C O 2 atmosphere.
2.2. Constructing GFP-GLP-1 Receptor. The cDNA clone
encoding the human GLP-1 receptor in pBluescript SK
with the size ≈1.6kb was subcloned into EcoRI site of
either pEGFP-C3 or pcDNA3. CHO cells were transiently
transfected with GFP-GLP-1 receptor or wild type GLP-
1 receptor. Fluorescent derivative was analyzed by using
confocal microscopy and immunoblotting. All cDNA clones
were veriﬁed by sequencing.
2.3. Overexpression of GFP-GLP-1 Receptor and GLP-1
Receptor in CHO Cells. CHO cells were plated in 24-well
plates at 5 × 104 cells/well and incubated 24 hours in
growth medium supplemented with 10% fetalbovine serum.
Cells were washed with HBSS for 2 times and incubated
in 0.4mL growth medium supplemented with 0.1mL of
OPTIMEM-1 medium with 1.0μg plasmid DNA/well, 2.5μL
LipofectAMINE2000/1.0μgo fD N Af o r2 4o r4 8h o u r sa t
37◦C[ 32]. The same procedure was used to express GFP-
GLP-1 receptor in Rin m5F cells.
Cells were plated in 6-well plates at 50 × 104 cells/well
and incubated 24 hours in growth medium supplemented
with 10% fetal bovine serum. Cells were washed with HBSS
for 2 times and incubated in 1.5mL growth medium sup-
plemented with 0.5mL of OPTIMEM-1 medium with 4.0μg
plasmid DNA/well, 12.5μL LipofectAMINE2000/4.0μgo f
DNA for 24 or 48 hours at 37◦C.
2.4. Whole Cell Competition Binding Assay. After expressing
GLP-1 receptor in 24-well plates, CHO cells were rinsed
3 times with HBSS. Cells were incubated together with
100μL of 200pM [125I]GLP-1(7-36)amide (100pM/well)
and 100μL of binding buﬀer (0.2% BSA, 10mM NaHepes,
pH = 7.4 in HBSS) without or with GLP-1(7-36)amide
ranging from 10
−11 to 10
−6 Mf o r3 0m i n u t e sa t3 7 ◦C. After
incubation, the cells were transferred on ice and washed 3
times with a binding buﬀer. The total cellular radioactivity
was determined by scraping the cells in 0.5mL of lysis
buﬀer (1% SDS (w/v), 0.2M NaOH) and counted in a
gamma counter. The speciﬁc binding was determined by
subtracting the nonspeciﬁc binding obtained in the presence
of 10
−6 M unlabelled GLP-1(7-36)amide from the total cell
associated radioactivity. The same procedure was used to
determine the binding of GLP-1(7-36)amide to endogenous
receptor in Rin m5F cells (plated at 3.25 × 105 cells/well for
48 hours). Meanwhile, competition binding assay for GFP-
GLP-1 receptor was carried out in 6-well plates with 200μL
of[125I]GLP-1(7-36)amideand200μLofbindingbuﬀerwith
or without GLP-1. The rest remains the same.
2.5. Membrane Preparation. After expressing a recombinant
GLP-1 receptor and GFP-GLP-1 receptor in 6-well plates,
CHO cells were harvested by scraping and processed for
plasma membranes according to the protocol (Bavec 2004a),
but with minor modiﬁcations. Cells (for approximately
7.5 × 106) were centrifuged at 500×gf o r1 0m i n u t e sa n d
suspended with 0.75mL of ice-cold lysis buﬀer (50mM
NaHepes, pH = 8.0, 0.1mM EDTA, 3mM MgCl2, 100mM
NaCl, 10 mM β-mercaptoetanol, and protease inhibitors
2μM pepstatin and 1mM phenylmethylsulphonyl ﬂuoride).
Cells were lysed by Teﬂon/glass Potter homogenizer for 10
times at 1500rpm. Cell lysates were centrifuged at 750×gf o r
10 minutes. The supernatant was centrifuged at 100.000×g
for 60 minutes. The resultant pellet was then suspended in
TE buﬀer (10mM Tris-HCl, 0.1mM EDTA; pH = 7.5) and
stored at −80◦C .A l lo p e r a t i o n sw e r ec a r r i e do u ta t4 ◦C.
The protein concentration in membrane preparations was
between 2.0 and 4.0 mg/mL as determined by Biorad Protein
Assay at 595nm.
2.6. GTPγS Binding Studies. The rate of [35S]GTPγS binding
to G-proteins from plasma membranes was followed as
previously described [33] with minor modiﬁcation. Brieﬂy,
the membranes (ﬁnal protein concentration in the assay
mixture in recombinant GLP-1 receptor and GFP-GLP-1
receptor enriched CHO plasma membranes preparation was
500μg/mL) were incubated with 5mM MgCl2, 1mM dithio-
threitol, 150mM NaCl, 1μMG D P ,a n d1 – 5n M[ 35S]GTPγS
(approximately 150.000–200.000cpm per assay) at 25◦Ci n
TE buﬀer (pH 7.5), for 5 minutes with or without 100nM
GLP-1(7-36)amide. The unbound [35S]GTPγS was washed
out by rapid ﬁltration of the reaction mixture through Milli-
pore GF/C glass-ﬁber ﬁlters under vacuum three times with
5m Lo fc o l dT Eb u ﬀer. After extraction of the radioactive
material overnight in 20mL of Emulsiﬁer-Safe (Packard,
USA) scintillation liquid, radioactivity was determined withJournal of Biomedicine and Biotechnology 3
LKB 1214 Rackbeta liquid scintillation counter. Blank values
were determined by the same procedure in samples in which
t h em e m b r a n e sw e r er e p l a c e dw i t hb u ﬀer.
2.7. Cyclic AMP Measurements. A f t e re x p r e s s i n g( 2 4h o u r s
posttransfection) GFP-GLP-1 receptor or GLP-1 receptor
in 6-well plates, CHO cells were rinsed once with HBSS.
Cells were incubated with 500μL of GLP-1(7-36)amide (100
nM/well) or 10μM forskolin in stimulating buﬀer (0.2%
BSA, 10mM NaHepes, pH = 7.4 in HBSS) for 15 minutes at
37◦C. After stimulation, stimulating buﬀer was removed and
replaced with 150μLo fT Eb u ﬀer (50mM Tris, 5mM EDTA,
pH =7.4).Cellswerelysedbyscraping,followedbyboilingat
100◦C for 5 minutes and centrifuged at 16000×g for 10 min-
utes. The supernatant was collected and the total content of
cAMPwasmeasuredbyaspeciﬁcradioimmunoassay(Amer-
sham). The same procedure was used to determine the accu-
mulation of cAMP in Rin m5F cells and CHO wild type cells.
2.8. Immunoblotting Analysis. After expressing GFP-GLP-1
receptor in 6-well plates, CHO cells were rinsed once with
HBSSandlysedwith0.2%TritonX-100.Celllysatewerecen-
trifuged at 750×g for 10 minutes. Pellet was resuspended in
TE buﬀer and used for further manipulation. Immunoblot-
ting analysis was performed as described previously [34,
35] with minor modiﬁcations. After the run on SDS-PAGE
(Hoefer SE600, 16cm long) with a current of 30mA (60mA
for two gels) for stacking (2.5mL 0.5M Tris-HCl, pH =
6.8, 1.5mL 40% acrylamide mix 37.5 : 1, 100μL 10%
SDS, 100μL 10% ammonium persulphate, 10μL TEMED,
5.8mL destillated water) and 45mA (80mA for two gels)
for running gel (7.5mL 1.5 M Tris-HCl, pH = 8.8, 8.25mL
40% acrylamide mix 37.5 : 1, 300μL 10% SDS, 300μL 10%
ammoniumpersulphate,20μLTEMED,14.25mLdestillated
water) for 2-3 hours (EPS 601, Amersham Biosciences) in
running buﬀer (3.0g Tris base, 14.4g glycine, 1.0g SDS in
1l destillated water), proteins were transferred from the gel
onto nitrocellulose membranes with a constant current of
400mA for 5 hours (TE 62 Transphor II) in transfer buﬀer
(1l methanol plus 3,5 l destillated water plus 500mL TB10x:
60gTrisbase,288gglycine).Therunandtransferofproteins
were cooled at 9◦C (MultiTemp III). The proteins on the
blotwerevisualizedwith0.2%PonceouSin5% CH3COOH.
After staining, the proteins were incubated for 1 hour in
blocking buﬀer (2% bovine serum albumin in TBS; 20mM
Tris-HCl, 500mM NaCl; pH = 7.5). The blocking buﬀer
was then replaced by a buﬀer TTBS (0.05% Tween 20 in
TBS) and incubated with the primary monoclonal mouse
IgG antiGFP (JL-8, Clontech, 1 : 8000) at room temperature
for2hours.Theprimaryantibodieswerewashedthree-times
in TTBS buﬀer for 10 minutes and incubated with secondary
peroxidase-conjugated goat antimouse IgG antibodies (1 :
1000, Calbiochem) at room temperaturefor 1 hour. After the
wash in TTBS buﬀer three-times for 10 minutes and once in
TBS for 10 minutes, the immunoreactive proteins caught on
the blot were exposed for 15–60 seconds to Kodak X-Omat
ﬁlmusingECLchemiluminescencedetectionkit(Amersham
Pharmacia Biotech, RPN 2106).
The same procedure was used to determine the expres-
sionofGLP-1receptorinCHOcells,except5%lowfattyacid
(0.6g/100g milk) milk in TBS for blocking; primary poli-
clonal rabbit IgG anti-GLP-1R (Bernard Thorens, Lausanne,
Switzerland, 1 : 1000) and secondary peroxidase-conjugated
goat antirabbit IgG antibodies (1 : 1000, Calbiochem) were
used in immunoblotting analysis. The rest remains the same.
2.9.ConfocalMicroscopy. CoverslipswithCHOcellsexpress-
ing GFP-GLP-1 receptor were examined with a Zeiss LSM
510 confocal microscope (Jena, Germany). The ﬂuorescent
images were collected by a plan-apochromatic oil immersion
objective (63 magniﬁcation and the numerical aperture 1.4)
using 488-nm Ar-Ion and 543-nm He-Ne laser excitation.
GFP-GLP-1 receptor and plasma membrane FM4-64 dye
ﬂuorescence were collected through the BP 505–530-nm and
LP 560-nm emission ﬁlters, respectively.
2.10. Insulin Release. After expressing GFP-GLP-1 receptor
in 6-well plates (50 × 104 cells/well), Rin m5F cells were
rinsed 3 times with HBSS. Cells were then incubated with
500μLo fb u ﬀer (0.2% BSA, 10mM NaHepes, pH = 7.4
in Krebs-Ringer bicarbonate buﬀer) without or with 10nM
GLP-1(7-36)amide for 60 minutes at 37◦C. Aliquots of
the incubation medium were taken for radioimmunoassay
of insulin [36]. Insulin secretion was expressed as μU
insulin/50×104 cells/h.
2.11. Calculations. Displacement binding data were analysed
using a nonlinear curve ﬁtting program (Graph Pad Prism 4)
andﬁttedto dose response curve. The bottom parameter was
ﬁxed and constant was equal to 0, and the top parameter was
put to a constraint to 100. Data are shown as mean ± SEM.
2.12. Statistics. Statistical analysis (one-way ANOVA) was
carried out by Prism 4 computer program (GraphPad Soft-
ware, USA), which was used also for graphical presentation
of the results. In ANOVA analysis Tukey-Kramer multiple
comparison test was used to reveal signiﬁcant diﬀerences
between groups of interest; P>. 05 was not considered
signiﬁcant.
2.13. Materials. CHO and Rin m5F cells were obtained
from ECACC, UK. Acrylamide/bis-acrylamide, SDS, and
Tris electrophoresis reagents were from Eurobio (France).
OPTIMEM-1 was from Gibco (UK). LipofectAMIN 2000
reagentwasfromInvitrogenLifeTechnologies(NewZaland).
ECL kit, low molecular protein markers, cAMP radioim-
munoassay kit, [125I]GLP-1(7-36)amide, and [35S]GTPγS
were obtained from Amersham Pharmacia Biotech, UK.
Tert-butyloxycarbonyl amino acids were from Bachem,
Switzerland, and Chemimpex, USA. Fetal bovine serum,
Dulbecco’s modiﬁed Eagle’s medium (DMEM), Hank’s Bal-
anced Salt Solution (HBSS), GLP-1(7-36)amide, forskolin,
TEMED, and ammonium persulphate were supplied from
S i g m aA l d r i c hC o ,U S A .N i t r o c e l l u l o s et r a n s f e rm e m b r a n e s
were from Schleicher and Schuell, Germany. Mouse mon-
oclonal anti-GFP (JL-8) was from Clontech, USA. Goat4 Journal of Biomedicine and Biotechnology
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Figure 1: Deduced amino acid sequence of the GFP-GLP-1 receptor. GFP (shaded box); MCS (underlined); 5 -untranslated region of the
clone hGLPR-6(20) (bold); human GLP-1 receptor (normal).
antirabbit IgG and goat antimouse IgG horseradish perox-
idase conjugates were from Calbiochem, USA. Emulsiﬁer-
Safe scintillation liquid was from Packard, USA. Insulin
radioimmunoassaykitwasfromMiliporeUSA.Tris-HCland
methanol were from Merck, Germany. MgCl2, NaCl, and
EDTA were from Kemika (Croatia). Biorad Protein Assay
was from BioRad, USA. Restriction and ligation enzymes
were from Fermentas; the cDNA clone encoding the human
GLP-1 receptor and anti-GLP-1R primary polyclonal rabbit
IgG antibodies were gift from Bernard Thorens (Lausanne,
Switzerland).
3. Results
3.1. Preparation, Expression, and Localization of the GFP-
GLP-1 Receptor. CHO cells were transiently transfected with
the N-terminal tagged enhanced green ﬂuorescent protein
to GLP-1 receptor called GFP-GLP-1 receptor. The deduced
amino acid sequence of the GFP-GLP-1 receptor (non-
glycosylated) with the theoretical Mw of 83.5kDa is repre-
sented in Figure 1. Cells expressing ﬂuorescent GFP-GLP-1
receptorareshowninFigure 2(a).Inaddition,theexpression
of the GFP-GLP-1 receptor in total membranes from CHO
cells was analyzed by SDS-PAGE and followed by protein
transfer from the gel onto nitrocellulose membrane. In
contrast to the control nontransfected cells (Figure 2(b),
lane 3) and EGFP-C3 transfected cells (Figure 2(b),l a n e2 )
protein immunostaining showed protein band with the Mw
of 90kDa (Figure 2(b), lane 1), which might correspond
to the glycosylated form (G¨ oke et al. 1994) of GFP-GLP-1
receptor. Much more apparent protein band with Mw of 70–
75kDa (Figure 2(b), lane 1) might correspond to the non-
glycosylated form of GFP-GLP-1 receptor. Other two protein
bands with Mw 180kDa and 276kDa were unidentiﬁed.Journal of Biomedicine and Biotechnology 5
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Figure 2:ExpressionanalysisofrecombinantGFP-GLP-1receptorfromCHOcells.(a)CHOcellsexpressingGFP-GLP-1receptorareviewed
under standard light conditions or under argon-ion laser light source (488nm) 24-hour posttransfection (merge pictures). (b) Western blot
analysis with the anti-GFP primary polyclonal mouse IgG antibodies. Lane 1: membranes with the GFP-GLP-1 receptor; lane 2: membranes
with the GFP; lane 3: membranes CHO. (c) Western blot analysis with the anti-GLP-1R primary polyclonal rabbit IgG antibodies. Lane 1:
membranes CHO; lane 2: membranes with the GFP-GLP-1 receptor; lane 3: membranes with the GLP-1 receptor. The amount of protein
loaded in each well in SDS-PAGE was 50μg.
Figure 3: Localization of the GFP-GLP-1 receptor. CHO cells
expressing GFP-GLP-1 receptor are viewed under argon-ion laser
light source (488nm) and helium-neon laser light source (543 nm)
24-hour posttransfection. Most of the protein is found outside of
the nucleolus, in internal membranes (GFP, green dye), but very
small amount in plasma membrane (FM4-64, red dye). Imaging is
performed 24–48 hours posttransfection.
We speculate that these high molecular weight protein
structures may result due to overexpression or/and high
temperature dependant protein aggregation. This promotes
formation of GFP-GLP-1 receptor oligomers, such as dimers
or tetramers. Protein band with 30kDa probably represents
GFP protein. Unfortunately, we were unable to detect
GFP-GLP-1 receptor, both 70–75kDa and 90kDa form,
with anti-GLP-1R antibodies (Figure 2(c)). It is most likely
that GFP tagging hinders epitopes on molecule of GLP-
1r e c e p t o r[ 30]. To examine the level of expression and
localization of GFP-GLP-1 receptor in CHO cells, confocal
imaging was performed. Approximately 25%–40% of CHO
cells were eﬃciently transfected with GFP-GLP receptor.
Most of the GFP-GLP-1 receptor was found outside the
nucleolus, in internal membranes (Figure 2(a) and Figure 3;
protein is dyed in green); meanwhile, its signal from plasma
membranes was very weak (Figure 3; plasma membranes are
dyed in red).
3.2. Characterization of GFP-GLP-1 Receptor Binding Prop-
erties. CHO cells transfected with the wild type receptor
construct prepared either in the pcDNA3 (GLP-1 receptor)
or in the pEGFP-C3 (GFP-GLP-1 receptor) vectors displayed
aﬃnity binding of GLP-1(7-36)amide with IC50 of 18.2 ±
0.8nMand8.9 ± 3.8nM, respectively (Table 1 and Figure 4)
at 25◦C. The number of binding sites for GLP-1 receptor
and GFP-GLP-1 receptor on surface of each CHO cell was
102500 ± 1700 and 1830 ± 220, respectively. The binding
GLP-1(7-36)amide to endogenous GLP-1 receptor from RIN6 Journal of Biomedicine and Biotechnology
Table 1: Eﬀect of GLP-1(7-36)amide on GLP-1 receptor binding
sites from Rin m5F cells and CHO cells transiently expressing
human GLP-1 receptor and GFP-GLP-1 receptor.
IC50 (nM) Bmax
(receptor/cell)
GLP-1 receptor from CHO cells 18.2 ±0.8 102500 ±1700
GFP-GLP-1 receptor from
CHO cells 8.9 ±3.8 1830 ±220
Endogenous GLP-1 receptor
from Rin m5F cells 0.56 ±0.02 1107 ±121
−5 −6 −7 −8 −9 −10 −11 −12
GLP-1(7-36) amide (log, M)
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Figure 4: Displacement of [125I] GLP-1(7-36)amide binding to its
receptor by GLP-1 from CHO cells. GLP-1 receptor (squares); GFP-
GLP-1 receptor (triangles). Each dot with the indicated standard
error represents the mean value of three independent experiments
done in triplicate (for GLP-1 receptor) and in duplicates (for GFP-
GLP-1 receptor). See Results for the details.
m5F cells showed lower values of IC50 = 0.56 ±0.02nM and
lower receptor expression with 1107 ± 121 binding sites per
cell (Table 1).
3.3. Functional Coupling of GFP-GLP-1 Receptor with G-
Protein. The binding of [35S]GTPγS to G-proteins in
plasma membranes from CHO cells is time dependent,
and one phase exponential association curve was ﬁtted to
the experimental data giving maximal [35S]GTPγS binding
of 467fmol/mg (data not shown). The apparently linear
part of the curve (0–5 minutes) was used to assess the
initial rate of [35S]GTPγS binding, and the following values
were obtained: 13.4fmol/mg/min for GFP-GLP-1 receptor,
9.8fmol/mg/min for GLP-1 receptor in CHO overexpressed
plasma membranes, and 11.1fmol/mg/min in the mem-
branes from nontransfected CHO cells. GLP-1(7-36)amide
increased the initial rate of [35S]GTPγS binding as compared
to the basal activity of CHO transfected cells. Maximal
increase of the initial rate of [35S]GTPγS binding was 72%
(P<. 01) over the basal for GFP-GLP-1 receptor and 67%
(P<. 05) over the basal for GLP-1 receptor transfected CHO
cells (Figure 5).
+ − + − + − GLP-1(7-36)
amide
0
50
100
150
200
[
3
5
S
]
G
T
P
γ
S
b
i
n
d
i
n
g
(
%
)
∗
∗
Figure 5: Eﬀect of GLP-1(7-36)amide on the initial rate of
[35S]GTPγS binding to the plasma membranes from CHO cells
transiently expressing GLP-1 receptor and GFP-GLP-1 receptor.
Mock (empty bar); GFP-GLP-1 receptor (ﬁlled bar); GLP-1
receptor (patterned bar). 100% = 11.1fmol/mg/min for CHO,
13.4fmol/mg/min for GFP-GLP-1 receptor, and 9.8fmol/mg/min
for GLP-1 receptor (basal values, no GLP-1(7-36)amide added).
Each bar with the indicated standard deviation represents the mean
valueofthreeindependent experiments doneinduplicate. ANOVA:
F(5, 12) = 9.95; P< .001. Tukey-Kramer multiple comparison test
was used to reveal signiﬁcant diﬀerences between groups of interest.
See Results for the details.
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Figure 6: Eﬀect of GLP-1(7-36)amide and forskolin on the produc-
tionofcAMPfromCHOcellstransientlyexpressingGLP-1receptor
and GFP-GLP-1 receptor. GLP-1 receptor (empty bar); GFP-GLP-1
receptor (ﬁlled bar). 100% = 56.8fmol/mg and 37.7fmol/mg for
GLP-1 receptor and GFP-GLP-1 receptor, respectively (basal value,
no ligand added). Each bar with the indicated standard deviation
represents the mean value of three independent experiments done
in duplicate. ANOVA: F(5, 12) = 98.14; P< .0001. Tukey-Kramer
multiple comparison test was used to reveal signiﬁcant diﬀerences
between groups of interest. See Results for the details.
3.4. The Eﬀect of GFP-GLP-1 Receptor on cAMP Production.
We further demonstrated the coupling of the GFP-GLP-
1 receptor to adenylyl cyclase. GLP-1(7-36)amide induced
cAMP production from GFP-GLP-1 receptor and GLP-1
receptor-transfected CHO cells revealed 2900% (P< .001)
and 5400% (P< .001) increase over the basal, respectively
(Figure 6). The observed eﬀect in both types of transfectedJournal of Biomedicine and Biotechnology 7
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Figure 7: Eﬀect of GLP-1(7-36)amide and forskolin on the produc-
tion of cAMP from CHO and Rin m5F cells. Wild type CHO cells
(empty bar); Rin m5F cells (ﬁlled bar). 100 % = 46.7 fmol/mg and
40.9 fmol/mg for CHO cells and Rin m5F, respectively (basal value,
no ligand added). Each bar with the indicated standard deviation
represents the mean value of three independent experiments done
in duplicate. ANOVA: F(5,12) = 31250; P< .0001. Tukey-Kramer
multiple comparison test was used to reveal signiﬁcant diﬀerences
between groups of interest. See Results for the details.
cells was increased 12- and 22-fold, respectively, in com-
parison with the eﬀect on Rin m5F cells that naturally
express GLP-1 receptor. This means that the production of
cAMP in Rin m5F cells was increased up to 240% (P< .05)
of the basal in the response to maximally stimulating
concentration of GLP-1(7-36)amide (Figure 7). Wild type
CHO cells without GLP-1 receptor show no eﬀect upon
stimulation by a hormone (Figure 7). The stimulation of
cAMP production in response to forskolin was signiﬁcantly
increased by both cell types (P< .001). GFP-GLP-1 receptor
cells are not more sensitive to forskolin in comparison
to GLP-1 receptor cells, because ANOVA analysis Tukey-
Kramermultiplecomparisontesthasnotrevealedsigniﬁcant
diﬀerences between these groups of interest.
3.5. The Eﬀect of GFP-GLP-1 Receptor on Insulin Release.
In Rin m5F cells, GLP-1 stimulated insulin release more
than 3-fold as compared to basal release (P< .05), (Table 2).
Cells transfected with the GFP-GLP-1 receptor vectors
signiﬁcantly displayed 14.5-fold GLP-1 dependent increase
in insulin release (P< .001) (Table 2).
4. Discussion
In the present report we localized N-terminally GFP-tagged
GLP-1 receptor in CHO cells and characterized its binding
properties and the coupling to the G-proteins and adenylyl
cyclase. Our ﬁndings show that (1) the fusion protein is pri-
marily localized on the internal membranes near nucleous,
while its concentration on the plasma membrane is low; (2)
two types of the fusion proteins might be localized on the
membranes,nonglycosylatedontheinternalmembranesand
glycosylated type on the plasma membrane; (3) the fusion
protein which speciﬁcally binds the GLP-1 on the cell surface
Table 2: Eﬀect of GLP-1(7-36)amide on insulin release from Rin
m5F cells transiently expressing human GFP-GLP-1 receptor. Each
bar with theindicated standard deviation represents themean value
of ﬁve independent experiments done in duplicate. ANOVA: F(3,
16) = 291.6;P <.0001.Tukey-Kramermultiplecomparisontestwas
used to reveal signiﬁcant diﬀerences between groups of interest.
Condition Insulin release
(μU/50 ×104 cells/h)
Basal (no addition of GLP-1(7-36)amide) 21.5 ±1.7
+ GLP-1(7-36)amide 69.9 ±5.4
∗
+ GFP-GLP-1 receptor 26.9 ±3.2
+ GFP-GLP-1 receptor +
GLP-1(7-36)amide 388.5 ±45.6
∗∗
∗P< .05 versus basal (no addition).
∗∗P< .001 versus + GFP-GLP-1 receptor.
and when activated is able to transfer the signal to adenylyl
cyclase via heterotrimeric G-proteins and induces insulin
release.
It is evident that, depending on the site of GFP insertion,
thetagging canproducesubstantialchangesinthe properties
of the receptors. Whereas GFP tagging does not seem to alter
the function of some receptors [37–39], it is known that for
some receptors GFP alters their function[40,41], membrane
localization [42], or rate of membrane incorporation [43].
There is no general rule which site of GFP insertion presents
betterGFPtagging.InsomecasesN-terminusisbetterchoice
than C-terminus [39] and vice-versa [37]. C-terminally
GFP-tagged GLP-1 receptor neither is displaying the same
membrane localization as its wild type [31]n o ri sf u l l y
characterized regarding receptor binding data, G-protein
activation and coupling to its downstream eﬀectors such as
adelylyl cyclase or PLC [30]. With this question in mind,
we synthesized and analyzed the properties of N-terminally
GFP-tagged GLP-1 receptor expressed in CHO cells.
Regarding the spatial distribution of GFP-GLP-1 recep-
tor, the overall ﬂuorescence was strongly polarized to the
region near the nucleolus. Contrary, ﬂuorescence in plasma
membranes was very weak. Immunolabeling of GFP-GLP-1
receptor on nitrocellulose membrane showed more than one
protein band. Intensity of protein bands with the molecular
weight of 90kDa and 71kDa, which might correspond to
glycosylated and nonglycosylated forms of receptor, respec-
tively, perfectly correlates with the amount of ﬂuorescence in
plasma membrane and region near nucleolus, respectively.
Glycosylation of GLP-1 receptor is a precondition for regular
receptor translocation to plasma membrane [44], but not
for the receptor binding. We do not have direct biochemical
proof for glycosylation state of the receptor, but Figure 2(b)
shows that most of the receptor might be nonglycosylated.
This raises the possibility that either the tag interferes with
glycosylation of the receptor and blocks its translocation
from endoplasmatic reticulum and Golgi apparatus to
plasma membrane or it is misfolded, and most receptors do
not reach the compartments, where glycosylation occurs. In
addition, only a minority of GFP-GLP-1 receptor is properly
glycosylated and translocates to plasma membrane (Figure 2
and Table 1).8 Journal of Biomedicine and Biotechnology
The functionality of the GFP-GLP-1 receptor was
assessed by measuring its binding properties and the cou-
pling to the G-proteins and adenylyl cyclase, followed by
insulin release. Tagging GFP to the amino terminus led to
receptor that showed very similar binding aﬃnity and G-
protein coupling but accumulated lower concentration of
cAMP in response to agonist application (Figures 4, 5,a n d
6). In addition, reduced accumulation of cAMP was due to
reduced number of receptors in plasma membrane. Reduced
number of receptors (Table 1) was correlated with decreases
in both amount of protein (Figure 2(b)) and ﬂuorescence
(Figure 3) in plasma membrane. Reduced number of recep-
tors should also reduce the eﬀect on G-protein coupling.
But it did not. Why the eﬀect on G-protein coupling was
not reduced? In this experiment we have used the total
membrane preparation instead of the whole cell system.
The number of the tag and wild type receptors was equal
and resulted in the same eﬀect on G-protein coupling in
both membrane preparations. This means that both types
of GFP-GLP-1 receptors localized, in plasma membrane and
in internal membranes, are functional and able to transfer
the signal to G-proteins (Figure 5). Additionally, after GLP-
1 stimulation GFP-GLP-1 receptor signiﬁcantly induced
insulin release from Rin m5F cells (Table 2).
OurresultsshowthatGFPtaggingtotheaminoterminus
can alter the properties of GLP-1 receptor. In spite of these
minor alternations in functionality of the receptor we believe
that N-terminally GFP-tagged GLP-1 receptor is useful tool
for further studies such as receptor dynamics, expression,
signaling,andoligomerization.Combiningdiﬀerentmodern
in vivo and in silico biology methods [45, 46]w i l lh e l pi n
investigationofnewsyntheticandnaturalligandsofreceptor
for the treatment of diabetes mellitus type 2.
Abbreviations
GPCR: G-protein coupled receptor
GLP-1: Glucagon-like peptide-1
GFP- GLP-1: GFP-tagged GLP-1
GFP: Green ﬂuorescent protein.
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